---
run_id: halo-evidence-vs-diagnosis-validation-v11-vanilla-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: vanilla
run_number: 5
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 501
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
condition_packet_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
output_file: model-outputs/vanilla-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `vanilla`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 501, on the frozen condition packet.

## Output

I recommend you commit to the **Claim File Review**.

### The Recommendation
You should advise the CEO to prioritize the Claim File Review over all other options.

Your current "strong quarter" is a lagging indicator driven by sales incentives (bundle pricing) and executive optimism (roadmap pitches), not product-market fit. The core of your business is a B2B workflow tool; therefore, the only metric that matters is whether the software actually solves the problem for the end-user.

The Usage Quality Sprint measures *quantity* (which is currently inflated by managers running samples), and the Commercial Cleanroom measures *willingness to pay* (which is currently skewed by the fear of losing a "centerpiece" feature). Neither tells you **why** front-line adjusters are abandoning the tool after two days or why health-liability users can't justify the output to reviewers.

The Claim File Review is the only option that exposes the "truth" of the workflow. By auditing actual files, you will discover if SignalPath is providing genuine value or if it is simply a "management theater" tool that looks good in a demo but fails in the trenches. This is the only data set that can inform whether you should scale, pivot, or narrow your focus.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and provides a small sample size compared to the automated data of the Usage Quality Sprint or the revenue data of the Commercial Cleanroom. In a high-pressure environment where the board wants to see "scale" and "growth," presenting qualitative findings from a handful of files can seem anemic or overly cautious compared to the "hard numbers" of expansion bookings.

### The Evidence That Would Change My Mind
I would change this recommendation if the "wrong recommendation" tickets in the training channel showed a clear, singular technical bug that—once fixed—immediately restored adjuster usage across all segments. If the friction is a simple UI/UX bug rather than a fundamental failure of the logic or explainability (the "black box" problem in health-liability), then the **Usage Quality Sprint** becomes the superior choice to track the recovery of those users.
